AzTrials
AzTrials

Trigeminal NeuralgiaNCT06779578

Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia

A study testing Bipolar pulsed radiofrequency and Mopolar pulsed radiofrequency in people with Trigeminal Neuralgia and Refractory Pain, run by Alexandria University at 2 sites in Egypt.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia. Read more about this study

Who is it for?
Any age
Conditions the study is for
Trigeminal Neuralgia, Refractory Pain
What is being tested?
Bipolar pulsed radiofrequency and Mopolar pulsed radiofrequency
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
2 sitesEgypt
Study dates
1 Jan 2024to 1 Sep 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Patients with a definitive diagnosis of classical TN based on the third version of the International Classification of Headache Disorders (ICHD-3).
  • Either purely paroxysmal classical TN or classical TN with concomitant chronic pain.
  • Patients with idiopathic TN, with symptomatic clinical topography of V2 and/or V3.
  • Patients with brain magnetic resonance imaging (MRI) unremarkable for structural etiology for the trigeminal pain.
  • Patients with medically refractory TN defined as pain persisting beyond three months at a level of ≥5/10 after monotherapy or polytherapy in appropriate medical doses.

Who cannot join

  • Painful trigeminal neuropathy based on the third version of the International Classification of Headache Disorders (ICHD-3).
  • Trigeminal neuralgia with V1 symptomatic clinical topography.
  • Trigeminal neuralgia comorbid with other atypical facial pain disorders.
  • Structural TN e.g., due to vascular compression, posterior fossa tumors, central demyelination, …etc.
  • Patients exposed to previous radiofrequency procedures, as this may impair the nerve response to current PRF.
  • Patients who refused to participate in the study.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Egypt2 sites, 2 recruiting
  • Alexandria University Faculty of Medicine

    Alexandria, 21517

    Eman Hamdy, PhD

    Recruiting
  • Cairo University Kasr Alainy Faculty of Medicine

    Cairo

    Ahmed Elshal, PhD

    Recruiting

Other trials in Egypt

About this study

Official title: The Efficacy and Safety of Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia: An Exploratory Study

A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia.

Read the detailed description

This will be a prospective exploratory that will be conducted on patients with the inclusion and exclusion criteria detailed.

At the baseline visit, the sociodemographic data (age, sex, smoking status) and clinical data (TN etiology (idiopathic or symptomatic), TN phenotype (purely paroxysmal or with concomitant continuous pain), clinical symptoms topography (V2, V3), brain MRI findings, previous medications and interventions, and comorbidities) will be collected. The patients will be randomly assigned to undergo bipolar PRF or monopolar PRF using a simple randomization technique.

Pain scores will be assessed using the nominal rating scale (NRS) at baseline, within two weeks postoperatively, and at 1-month, 3-month, and 6-month intervals. Patient satisfaction will be assessed within two weeks following the intervention on a five-point Likert scale (5 represents very good and 1 means very bad). Treatment success will be defined as at least a 50% reduction in pain scores. The duration to pain control and the duration to pain recurrence/rebound will be assessed at follow-up visits. The patient's postoperative need for medications or further pain interventions will be detailed. Intraoperative and postinterventional complications will be monitored and documented.

Study interventions For the PRF procedure, all patients will be prepared in the operating room and will undergo standard operative monitoring (i.e., blood pressure, electrocardiography, and pulse oximetry). They will be positioned in a supine position with slight neck extension. Sedation will be provided (100 Ig fentanyl and 2 mg midazolam intravenously). Skin preparation will be performed using chlorhexidine.

I- Monopolar PRF In the monopolar PRF, an RF cannula (22-gauge, 100 mm, with a 10 mm active tip (SMK)) will be percutaneously advanced at the posterior border of the foramen ovale under fluoroscopic guidance. For confirming the detection of the mandibular nerve, sensory stimulation will be performed via the radiofrequency generator at a current of 0.5 to 1 V at a frequency of 50 Hz to elicit paresthesia response in the mandibular region. Motor stimulation will be performed via the generator at a current of 1 - 2 V applied at a frequency of 2 Hz to obtain a contraction response at the masseter muscle. After obtaining the appropriate responses, PRF will be applied at a fixed heat energy of 42 °C for a period of 240 seconds10.

II- Bipolar PRF For bipolar PRF, two RF cannulas will be advanced in the foramen ovale under fluoroscopic guidance. The first (22-gauge, 100 mm, and 10-mm active tip (SMK)) will be placed at the anterior border of the foramen ovale, and then the second (same parameters) will be advanced at the posterior border. The correct position will be confirmed on the lateral position until the correct placement at V2. Sensory and motor testing will be performed as aforementioned in the monopolar PRF to confirm the appropriate capture of the trigeminal nerve. Following obtaining the appropriate responses, PRF will be performed in two cycles, three minutes each, at a temperature of 42ºC and a current of 85 V and a 20-millisecond pulse width13.

Being tested
Bipolar pulsed radiofrequency, Mopolar pulsed radiofrequency
Keywords
trigeminal neuralgia, Radiofrequency ablation, Pulsed radiofrequency, Monopolar pulsed radiofrequency, Bipolar pulsed radiofrequnency
Medical subject headings
Trigeminal Neuralgia, Pain, Intractable

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bipolar pulsed radiofrequencyProcedure or surgery

    Bipolar pulsed radiofrequency ablation: the active comparator

  • Mopolar pulsed radiofrequencyProcedure or surgery

    Monopolar pulsed radiofrequency ablation: the placebo

Study groups in NCT06779578
Study groupRoleWhat they receive
Monopolar pulsed radiofrequncyPlacebo comparatorPatients with refractory TN undergoing monopolar pulsed radiofrequency
Receives: Procedure: Mopolar pulsed radiofrequency
Bipolar pulsed radiofrequencyActive comparatorPatients with refractory TN undergoing bipolar pulsed radiofrequency
Receives: Procedure: Bipolar pulsed radiofrequency

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Numerical pain scale (NRS)

    50% Pain reduction in the numerical rating scale (NRS)

    Measured: Two weeks, 1 month, 3 months, and 6 months

Secondary outcomes (1)
  1. Adverse events monitoring (Frequency, severity, seriousness, and causality)

    Frequency, type, and severity of adverse events. Classification of AEs as mild, moderate, or severe. Assessment of causality between the treatment and the AE

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jan 2025
  2. Study start1 Jan 2024
  3. Primary completion1 Jun 2025 (estimated)
  4. Study completion1 Sep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Explaratory
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06779578
Sponsor's protocol ID
0307084
Status last verified
Jan 2025
First submitted
13 Jan 2025
Last updated
17 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Bipolar pulsed radiofrequency and Mopolar pulsed radiofrequency in people with Trigeminal Neuralgia and Refractory Pain, run by Alexandria University at 2 sites in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Eman Hamdy, PhD (+201061402092, eman.ameen@alexmed.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Numerical pain scale (NRS) (time frame: Two weeks, 1 month, 3 months, and 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in